Wainwright HC Reiterates Recommendation to Buy Longboard Pharmaceuticals (LBPH)
Fintel reports that on July 11, 2023, HC Wainwright & Co. repeated Reported by Longboard Pharmaceuticals (NASDAQ: LBPH) with buy recommendation.
Analyst Price Expectations Suggest 141.78% Gains
One-year average as of July 6, 2023 target price 17.72 for Longboard Pharmaceuticals. Expectations range from lows of $11.11 to highs of $26.25. The average target price is up 141.78% from the latest reported closing price of 7.33.
see our corporate leaderboard The target price has the most upside potential.
Longboard Pharmaceuticals has an expected annual revenue of 0MM.Non-GAAP Annual Forecast EPS -2.29.
What is Fund Sentiment?
there is 53 fund or agency reporting positions at Longboard Pharmaceuticals. This is an increase of 7 owners or 15.22% over the previous quarter.Portfolio average weight out of all funds LBPH dedicated was 0.08%, an increase of 162.07%. Total shares owned by institutional investors increased by 80.88% to 13,308,000 shares in the last three months.
What are other shareholders doing?
combi set management owns 2,353,000 shares, representing 10.24% of the company. Earlier filings reported that the company owned 2,118,000 shares. will increase 9.98%.office increased Portfolio allocation to LBPH increased by 34.48% QoQ.
Farallon Capital Management holds 1,560,000 shares representing a 6.79% ownership interest in the company. Earlier filings reported that the company owned 810,000 shares. will increase 48.06%.office increased Portfolio allocation to LBPH increased 72.85% QoQ.
Price T Row Associates owns 1,465,000 shares representing a 6.38% ownership interest in the company. Earlier filings reported that the company owned 1,511,000 shares. Decrease 3.15%.office increased The portfolio allocation to LBPH increased by 12.20% quarter-on-quarter.
FBTAX – Fidelity Advisor Biotechnology Fund holds 1,432,000 shares representing a 6.23% ownership interest in the company. Earlier filings reported that the company owned 963,000 shares. will increase 32.76%.office increased Portfolio allocation to LBPH increased by 211.29% QoQ.
Point72 Asset management holds 1,250,000 shares representing a 5.44% ownership interest in the company.
Longboard Pharmaceutical Background Information
(This description was provided by us.)
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative new medicines for neurological disorders. Longboard was founded by Arena in January 2020 to drive a portfolio of core product candidates designed to highly select specific his GPCRs. Longboard’s small molecule product candidate was discovered from the same platform at Arena, the culmination of over 20 years of his GPCR research. Longboard is evaluating his LP352, an investigational oral centrally acting 5-hydroxytryptamine 2c receptor subtype superagonist, as a potential treatment for developmental and epileptic encephalopathy. Longboard also combines the centrally acting full cannabinoid type 2 receptor agonist LP143 and the centrally acting sphingosine in development as potential therapeutics for neurodegenerative diseases associated with neuroinflammation driven by microglial activation. We are also evaluating the -1-phosphate receptor subtype 1 and LP659. 5 modulators under development for potential treatment of central nervous system neuroinflammatory diseases.
Additional resources:
This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
Summarize this content to 100 words
Fintel reports that on July 11, 2023, HC Wainwright & Co. repeated Reported by Longboard Pharmaceuticals (NASDAQ: LBPH) with buy recommendation. Analyst Price Expectations Suggest 141.78% Gains One-year average as of July 6, 2023 target price 17.72 for Longboard Pharmaceuticals. Expectations range from lows of $11.11 to highs of $26.25. The average target price is up 141.78% from the latest reported closing price of 7.33.
see our corporate leaderboard The target price has the most upside potential. Longboard Pharmaceuticals has an expected annual revenue of 0MM.Non-GAAP Annual Forecast EPS -2.29. What is Fund Sentiment? there is 53 fund or agency reporting positions at Longboard Pharmaceuticals. This is an increase of 7 owners or 15.22% over the previous quarter.Portfolio average weight out of all funds LBPH dedicated was 0.08%, an increase of 162.07%. Total shares owned by institutional investors increased by 80.88% to 13,308,000 shares in the last three months. What are other shareholders doing? combi set management owns 2,353,000 shares, representing 10.24% of the company. Earlier filings reported that the company owned 2,118,000 shares. will increase 9.98%.office increased Portfolio allocation to LBPH increased by 34.48% QoQ. Farallon Capital Management holds 1,560,000 shares representing a 6.79% ownership interest in the company. Earlier filings reported that the company owned 810,000 shares. will increase 48.06%.office increased Portfolio allocation to LBPH increased 72.85% QoQ.
Price T Row Associates owns 1,465,000 shares representing a 6.38% ownership interest in the company. Earlier filings reported that the company owned 1,511,000 shares. Decrease 3.15%.office increased The portfolio allocation to LBPH increased by 12.20% quarter-on-quarter. FBTAX – Fidelity Advisor Biotechnology Fund holds 1,432,000 shares representing a 6.23% ownership interest in the company. Earlier filings reported that the company owned 963,000 shares. will increase 32.76%.office increased Portfolio allocation to LBPH increased by 211.29% QoQ. Point72 Asset management holds 1,250,000 shares representing a 5.44% ownership interest in the company. Longboard Pharmaceutical Background Information(This description was provided by us.) Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative new medicines for neurological disorders. Longboard was founded by Arena in January 2020 to drive a portfolio of core product candidates designed to highly select specific his GPCRs. Longboard’s small molecule product candidate was discovered from the same platform at Arena, the culmination of over 20 years of his GPCR research. Longboard is evaluating his LP352, an investigational oral centrally acting 5-hydroxytryptamine 2c receptor subtype superagonist, as a potential treatment for developmental and epileptic encephalopathy. Longboard also combines the centrally acting full cannabinoid type 2 receptor agonist LP143 and the centrally acting sphingosine in development as potential therapeutics for neurodegenerative diseases associated with neuroinflammation driven by microglial activation. We are also evaluating the -1-phosphate receptor subtype 1 and LP659. 5 modulators under development for potential treatment of central nervous system neuroinflammatory diseases.
Additional resources: This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-longboard-pharmaceuticals-lbph-buy-recommendation-0 Wainwright HC Reiterates Recommendation to Buy Longboard Pharmaceuticals (LBPH)